Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is a phase 1, open-label, three-period crossover study to evaluate the effect of Rabeprazole, a proton pump inhibitor, on the pharmacokinetics of DZD8586 (Birelentinib) under fasted and fed conditions in healthy participants.
Epistemonikos ID: cd47c58739137dc7d485dde72f57b4aa39e889d9
First added on: Oct 23, 2026